Heteractis magnifica sea anemones contain neuroprotective peptides that slow down the inflammation process and the deterioration of neurons in the development of Alzheimer’s. There is currently no treatment against this disease.
The Kunitz-type peptide HMIQ3c1was synthesized by scientists in a bacterial system (Escherichia coli) and is a recombinant analog of the peptide contained in the tentacles of tropical sea anemones Heteractis magnifica—marine sediment dwellers of the class Anthozoa. The sea anemones were collected near the Seychelles during a scientific marine expedition at the Akademik Oparin scientific and research ship. Genetic studies revealed a new group of Kunitz-type peptides in the sea anemone. Using the structure of the gene coding of one such peptide, a scientific team synthesized this peptide’s artificial analog in the lab of G.A. Belyakov Pacific Institute of Bioorganic Chemistry.
The synthesized peptide belongs to the new group of IQ-peptides that named after two first amino acid residues—isoleucine (I) and glutamine (Q). The substance has neuroprotective properties. Therefore, HMIQ3c1 inhibits the development of inflammation, including that fitting the Alzheimer’s model. Patients with Alzheimer’s disease are subject to various neurological disorders, including disorientation and memory loss.
Photo: Nick Hobgood/Wikimedia Commons
To view the Creative Commons license for the image, click here.